The pharmacological inhibition of TGF-β superfamily member myostatin is considered as another attractive therapeutic option for DMD patients, for both increasing muscle mass and helping regeneration via reduction of the non-permissive pro-fibrotic environment [114]. Here, TGFB1 is linked to Duchenne muscular dystrophy.